ImmuCell Corporation, a leader in developing products to improve cattle health and productivity, announced its preliminary, unaudited sales results for Q4 and the full year of 2025.
Total sales for Q4 2025 were $7.6 million, showing a slight decline compared to the same period in 2024.
For the full year 2025, total sales reached $27.6 million, demonstrating a 4.3% increase from the previous year.
Strong Sales Quarter
Q4 2025 exceeded expectations, indicating significant progress in market position recovery.
Strategic Focus on First Defense ®
Shift in focus following FDA Incomplete Letter for Re-Tain ® product, aiming to repurpose assets for First Defense ®.
Manufacturing Improvements
Implemented enhancements increased lyophilization process output by over 15% in 2025, with plans for similar growth in 2026.
- Sales for Q4 were higher than expected, showcasing market position growth and recovery efforts after supply challenges.
- Strategic refocus on First Defense ® reflects adaptability and proactive measures in response to regulatory challenges.
- Manufacturing improvements underline operational efficiency gains and capacity enhancements, supporting future growth objectives.
ImmuCell Corporation's strong sales performance in Q4 and throughout 2025, coupled with strategic initiatives and operational improvements, position the company for continued growth and success in the animal health sector.